(Total Views: 311)
Posted On: 05/08/2019 8:59:48 AM
Post# of 153764
That's interesting. Anyone thinking of Leronlimab here?
Q&A Gilead Q1 2019 results:
Phil Nadeau, Cowen and company:
“How do you see the treatment of HIV evolving over the next five to 10 years? And do you feel like Gilead's HIV pipeline has all the programs that it needs to stay competitive over that period?”
John McHutchinson Chief Scientific Officer & Head of Research & Development:
“And we believe that our ultimate goal with the long-acting regimen should be a subcutaneous at-home small volume, non-painful injection that's probably got two components to it, but it won't have that adherence issue to it and we'd like to be giving it every three months. That would be a great advance for patients as well.”
https://seekingalpha.com/article/4259400-gile...art=single
Q&A Gilead Q1 2019 results:
Phil Nadeau, Cowen and company:
“How do you see the treatment of HIV evolving over the next five to 10 years? And do you feel like Gilead's HIV pipeline has all the programs that it needs to stay competitive over that period?”
John McHutchinson Chief Scientific Officer & Head of Research & Development:
“And we believe that our ultimate goal with the long-acting regimen should be a subcutaneous at-home small volume, non-painful injection that's probably got two components to it, but it won't have that adherence issue to it and we'd like to be giving it every three months. That would be a great advance for patients as well.”
https://seekingalpha.com/article/4259400-gile...art=single
(0)
(0)
